All In Biotech

Drug Trial Radar · NCT06352073

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

May 16, 2024

Primary completion

Apr 16, 2026

Study completion Oct 27, 2026

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals; Sanofi
First posted
Apr 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE). This is an open-label study, meaning everyone in the study will receive dupilumab. Participants will have a screening visit where they will complete surveys and undergo an endoscopy (EGD). Blood and biopsies (small tissue samples) will also be collected. If eligible and enrolled into the study, participants will receive weekly subcutaneous (under the skin) injections of dupilumab for 52 weeks (one year). The first dose of dupilumab will be administered in the clinic at the enrollment visit (day 0) and participants (or their caregivers) will receive training on how to self-administer the remaining doses. Participants will return for study visits every at weeks 4, 8, 12, 18, 24, 30, 36, 44, and 52. During these visits, vital signs (temperature, heart rate, etc.) will be collected and participants will complete surveys. During visits at week 12, 24, and 52, blood will be collected and an endoscopy with biopsy will be performed. At 64 weeks (12 weeks after the last dose of dupilumab), participants assigned female at birth (AFAB) may be asked to come to the clinic for a urine pregnancy test.

Conditions

  • Eosinophilic Esophagitis
  • EoE

Interventions

  • DupilumabDrug

    300mg weekly subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Histologic Response to DupilumabTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.